Latest News
-
Tuesday - October 9, 2012
Not intended for U.S. and UK Media
European Commission gives green light to Bayer HealthCare’s Flexyess®
Flexyess is the first combined oral contraceptive with a flexible extended dosing regimen offering women "personal period planning" » more
-
Friday - October 5, 2012
Successful partnership with TU Dortmund University
Bayer Technology Services honors outstanding graduates in biochemical and chemical engineering » more
-
Thursday - October 4, 2012
Not intended for U.S. and UK Media - What people with diabetes do really need
Bayer HealthCare supports individualized diabetes treatment
A patient-oriented approach is pivotal of successful blood glucose therapy » more
-
Thursday - October 4, 2012
Bayer MaterialScience honored by AkzoNobel A&AC with “The Alliance Award”
Reliable partner for innovative and sustainable products » more
-
Tuesday - October 2, 2012
Innovative materials for ambitious project:
Bayer deepens involvement in futuristic Solar Impulse aircraft
Takeoff for fuel-less around-the-world flight scheduled for early 2015 » more
-
Monday - October 1, 2012
Joint venture building approximately 50 million euro chemical plant in eastern Germany:
High-tech plastic from Bayer driving investment
Sharply rising demand for specialty material Apec® » more
-
Monday - October 1, 2012
Not intended for U.S. and UK Media
Bayer HealthCare enters into multi-target alliance to fight endometriosis » more
-
Monday - October 1, 2012
Not intended for US or UK use! - Bayer Launches New Mobil Application (APP)
App ‘SKIN PEACE’ advises How to Use Topical Corticosteroid for Eczema Correctly » more
-
Friday - September 28, 2012
Not intended for US or UK use! - Atopic Dermatitis: CALM-IT Task Force at EADV 2012
Pruritus Relief within the First Hours after Application of Methyl-prednisolone Aceponate 0.1% to Treat Nickel Sulfate-Induced Eczema » more
-
Friday - September 28, 2012
Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan » more
-
Thursday - September 27, 2012
Not Intended for U.S. and U.K. Media
Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Stivarga shown in a pivotal Phase III trial to extend overall survival in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after previous treatments » more
-
Thursday - September 27, 2012
Not intended for US or UK use! - EADV Congress 2012
International consensus group introduces recommendations and treatment algorithms for hemorrhoidal disease » more
-
Thursday - September 27, 2012
Not intended for US or UK use! - EADV Congress 2012
New data suggest an increase in reactive oxygen species in the antibacterial action of isoconazole nitrate » more
-
Wednesday - September 26, 2012
Support of Family Planning Programs:
Bayer Joins Global Initiative for Better Access to Safe and Effective Contraception
Initiative includes the Government of Norway and other partners as well as Bayer HealthCare as the manufacturer of the contraceptive implant Jadelle / Bayer HealthCare prepared to halve the price of its WHO prequalified contraceptive implants Jadelle subject to certain volume guarantees / Initiative complements Bayer HealthCare's overall commitment to “Access to Medicine” focusing on Neglected Tropical Diseases like Chagas disease in Latin America and the African sleeping sickness (in cooperation with WHO), as well as tuberculosis (together with the TB Alliance) » more
-
Wednesday - September 26, 2012
Exemplary rehabilitation of a commercial building in Bottrop:
Bayer’s network of experts supporting future building in Germany
Comprehensive modernization through EcoCommercial Building Program / Combination of measures expected to produce energy surplus » more
-
Saturday - September 22, 2012
International award from Bayer Science & Education Foundation:
Climate researcher Markku Kulmala honored with Bayer Climate Award 2012
Honored for pioneering work on aerosols as a climate factor / Bayer Board of Management member Wolfgang Plischke: “To solve global challenges, we need innovative research contributions” / Prize awarded at Annual Assembly of Leopoldina in Berlin » more
-
Friday - September 21, 2012
Not intended for U.S. and UK media
U.S. FDA Approves EYLEA® (aflibercept) Injection for the Treatment of Central Retinal Vein Occlusion
Bayer plans to submit for marketing authorization in CRVO end of 2012 in Europe » more
-
Friday - September 21, 2012
Not intended for U.S. and UK Media
VEGF Trap-Eye (aflibercept ophthalmic injection) Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Decision of European Commission on approval expected in fourth quarter 2012 » more
-
Thursday - September 20, 2012
For use outside the US and UK only
Bayer submits marketing application for new transparent low dose contraceptive patch in the EU » more
-
Thursday - September 20, 2012
Bayer CropScience: Geared for Sustainable Growth
EUR 7 billion investment program to fuel further growth
EUR 5 billion earmarked for Research and Development between 2011 and 2016 / Investments of EUR 2 billion in production capacities and seed processing facilities / Strong integrated pipeline with at least EUR 4 billion peak sales potential / Share of Seeds business to double to 20 percent by 2016 » more
Copyright @ Bayer AG